Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from six to seven directors with John Doux, M.D. appointed as a Class III director.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from six to seven directors with John Doux, M.D. appointed as a Class III director
- Dermatology and rare-disease investment expertise strengthens strategic and clinical oversight
- Nasdaq-independent director with prior Palvella board experience before its reverse merger
- 6,000-share option grant vesting monthly over 36 months, subject to continued service
- Initial director term expires at the 2026 Annual Meeting of Stockholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.